Why the study?
Do circulating and imaging biomarkers enhance cardiovascular risk prediction in men with erectile dysfunction?
Do circulating and imaging biomarkers enhance cardiovascular risk prediction in men with erectile dysfunction?
Current evidence is limited regarding the utility of circulating and imaging biomarkers to enhance cardiovascular risk prediction in men with erectile dysfunction, highlighting the need for future randomized trials.
Limited evidence precludes biomarker-guided CV risk stratification in ED; leaves open incremental value pending dedicated prospective trials.
A number of circulating and imaging biomarkers are robustly associated with cardiovascular (CV) risk. The overall expectation from a biomarker in the erectile dysfunction (ED) setting is to enhance the optimal management of a man with this disorder but no clinical atherosclerosis. Evidence demonstrating that these biomarkers enhance risk prediction for individuals with ED is at this stage still limited for most of them. A better identification of the subsets of the ED population that require further risk stratification, as well as the initiation of randomized trials that will formally test the ability of biomarkers to predict CV risk, could make biomarker-guided prevention an attainable goal.
No takes yet. Share an insight, caveat, or question.
Vlachopoulos et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: